Wall Street analysts predict significant gains for two biotech stocks: Viking Therapeutics and CRISPR Therapeutics. Viking is projected to rise around 240% in the next 12 months, driven by its weight loss drug VK2735 entering phase 3 trials in Q2 2023. The weight loss drug market is forecasted to reach $100 billion in a few years. Meanwhile, CRISPR Therapeutics anticipates an 84% increase as it pushes forward with its gene-editing treatment, Casgevy, recently approved for blood disorders.
Viking Therapeutics (NASDAQ: VKTX) saw its stock decline after a previous surge from positive phase 2 trial data but continues to work on both injectable and pill versions of VK2735. Conversely, CRISPR Therapeutics (NASDAQ: CRSP) aims to bolster revenues this year following Casgevy’s launch and has multiple ongoing trials for various health conditions, potentially opening new markets.
Both companies have upcoming catalysts that could impact stock performance significantly, making these stocks of interest for growth-focused investors.
